Clinical trials: Elderly Immune Senescence
HIV - Human Immunodeficiency Virus
Effect of Extra Virgin Olive Oil Consumption on the Occurrence of Cardiovascular Events in Population Living With HIV
Study Summary: OLEUM VIHTAEGeneral Information Sponsor: Fundación SEIMC - GESIDA Study Title: Effect of Extra Virgin Olive Oil (EVOO) consumption on the occurrence of cardiovascular events in people living with HIV.
- Trial name
- OLEUM VIHTAE (NCT07761819)
- Testing
- The patients must ingest 50 mL of extra virgin olive oil daily
- Where
- Spain
- Volunteers
- 1,324 people
- Sponsor
- Fundacion SEIMC-GESIDA
Elderly Immune Senescence
Pilot Study to Evaluate Immunopotentiating Effects of Immulina in Elderly Individuals
This will be a small study aimed at determining the effects of oral Immulina consumption on the immune system in elderly individuals.
- Trial name
- NCT01784692
- Testing
- Immulina
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- University of Mississippi Medical Center
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Efficacy and Safety of Conventional Immunosuppressant Therapies in Elderly Patients With Neuromyelitis Optica Spectrum Disorder
Newly diagnosed NMOSD patients
- Trial name
- NCT07032337
- Volunteers
- 2,985 people
- Sponsor
- Samsung Medical Center
Multiple Myeloma
Study of Carfilzomib Weekly Plus Melphalan and Prednisone in Untreated Symptomatic Elderly Multiple Myeloma
IFM 2012-03 protocol is a Phase 2 multicenter nonrandomized open in elderly patients with multiple myeloma at diagnosis. Study primary objectives are in the first step to determine Maximum tolerated dose (MTD) of Carfilzomib…
- Trial name
- IFM2012-03 (NCT02302495)
- Testing
- Carfilzomib
- Where
- 33 sites in France
- Volunteers
- 32 people
- Sponsor
- University Hospital, Lille
Asthma
A Study of Depemokimab in Participants of 6 to 11 Years of Age
This study is aimed at assessing depemokimab as an add-on medicine for the treatment of asthma with type-2 inflammation in participants of 6 to 11 years of age.
- Trial name
- GLIDE (NCT07671001)
- Testing
- Depemokimab
- Where
- 3 sites in United States
- Volunteers
- 34 people
- Sponsor
- GlaxoSmithKline
Allergic Rhinitis
Special Drug Use Observational Study of Xolair in Patients With Severe to Most Severe Seasonal Allergic Rhinitis Aged ≥ 12 Years and < 18 Years Whose Symptoms Were Inadequately Controlled Despite to Conventional Therapies
This was a multicenter, uncontrolled, open-label, special drug use study to investigate the safety and efficacy of Xolair by collecting data in its clinical setting in patients with severe to most severe seasonal allergic…
- Trial name
- NCT04648930
- Testing
- Xolair
- Volunteers
- 50 people
- Sponsor
- Novartis Pharmaceuticals
Lymphoma
Radiation Therapy and High-Dose Corticosteroids in Treating Older Patients With Primary CNS Non-Hodgkin's Lymphoma
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Combining radiation therapy with a corticosteroid, such as dexamethasone, may be an effective treatment for non-Hodgkin's lymphoma.
- Trial name
- NCT00003278
- Testing
- dexamethasone, radiation therapy
- Where
- 14 sites in United States, Canada
- Volunteers
- 28 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Diffuse Large B-cell Lymphoma
Phase II Prospective Trial of Addition of Rituximab to Reduced Dose CHOP Chemotherapy in DLBC L Patients Aged 65 Years and Over
This is Phase II prospective trial of addition of rituximab to reduced dose CHOP chemotherapy in DLBC L patients aged 65 years and over.
- Trial name
- NCT02792491
- Testing
- Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
- Volunteers
- 57 people
- Sponsor
- Pusan National University Hospital
Leukemia
Rituximab Maintenance Versus Observation After First-line Immunochemotherapy by FCR in Older Patients With Chronic Lymphocytic Leukemia
RATIONALE: Classical chemotherapy does not cure advanced chronic lymphocytic leukemia (CLL) despite new drugs. Rituximab is a monoclonal antibody directed against CD20 surface antigen on B lymphocytes and leads to apoptosis of…
- Trial name
- LLC2007SA (NCT00645606)
- Testing
- Rituximab
- Where
- France
- Volunteers
- 542 people
- Sponsor
- University Hospital, Tours
Chronic Lymphocytic Leukemia
Ruxolitinib in the Treatment of Chronic Lymphocytic Leukemia
The purpose of this study is to determine if Ruxolitinib, an inhibitor of cytokine-signaling, is effective in the treatment of patients with Chronic Lymphocytic Leukemia for whom conventional chemotherapy is either too toxic or…
- Trial name
- NCT02015208
- Testing
- Ruxolitinib
- Where
- Canada
- Volunteers
- 13 people
- Sponsor
- Sunnybrook Health Sciences Centre
Hodgkin Lymphoma, Coexisting Medical Conditions
Study Of Nivolumab Alone, Or In Combination With Vinblastin In Patients With Classical Hodgkin Lymphoma
This study is a multicentric phase II open-label trial consisting of 6 cycles Nivolumab (2 weeks interval) followed by a PET-CT scan. The treatment will be allocated according to PET and CT scan responses.
- Trial name
- NCT03580408
- Testing
- Nivolumab, Vinblastin
- Where
- 51 sites in Belgium, France
- Volunteers
- 64 people
- Sponsor
- The Lymphoma Academic Research Organisation
Age Associated Immune Deficiency, Elderly Infection
Immunophenotype of Risk in Older Patients Admitted for Pneumonia
The objective is to evaluate if the immune risk phenotype (IRP) in patients who have been admitted for pneumonia predisposes to worse long-term outcomes.
- Conditions
- Age Associated Immune Deficiency, Elderly Infection, Pneumonia, Nutrition Disorders in Old Age
- Trial name
- NCT04062799
- Testing
- no intervention
- Where
- Spain
- Volunteers
- 174 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Rotavirus
A Study of the Safety and Immune Response to RotaTeq™ Vaccine in the Elderly (V260-027)
This is a Phase I clinical trial including 2 parts to evaluate the safety and immune response to RotaTeq™ /placebo in subjects of 65 to 80 years of age.
- Trial name
- NCT00836498
- Testing
- Comparator: RotaTeq
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Milk Allergy, Anaphylaxis
Safety of Oral Immunotherapy for Cow's Milk Allergy in School-aged Children
The purpose of this study is to study the number of Participants with Adverse Events as a Measure of Safety and Tolerability.
- Trial name
- NCT01361347
- Testing
- milk
- Where
- Finland
- Volunteers
- 28 people
- Sponsor
- Tampere University Hospital
Dermatitis Atopic
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids
This is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo controlled, 3-arm study for treatment of participants diagnosed with moderate-to-severe atopic dermatitis (AD) with a history of…
- Trial name
- SHORE (NCT06224348)
- Testing
- Amlitelimab, Topical corticosteroids, Topical calcineurin inhibitors
- Where
- 167 sites in United States, Argentina and 12 more
- Volunteers
- 643 people
- Sponsor
- Sanofi
Antibodies Involved in Healthy Aging
Wellderly Immune Antibodies Study, a Sub-Study of Healthy Elderly Active Longevity (HEAL) Cohort
The aim of this sub-study is to determine whether healthy individuals over 90 years of age possess immune cells that are involved in protection from chronic disease.
- Trial name
- NCT01816880
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Scripps Translational Science Institute
Dermatitis, Atopic
Study to Evaluate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis
B7451012 is a Phase 3 study to evaluate PF-04965842 in patients aged 12 years and older with a minimum body weight of 40 kg who have moderate to severe atopic dermatitis.
- Trial name
- JADE Mono-1 (NCT03349060)
- Testing
- PF-04965842 100 mg, PF-04965842 200 mg
- Where
- 88 sites in United States, Australia and 6 more
- Volunteers
- 387 people
- Sponsor
- Pfizer
Multiple Myeloma
Study to Demonstrate Clinical Benefit of Lenalidomide and Dexamethasone
Recent prospective multicenter phase II study assessed the efficacy and tolerability of lower dose lenalidomide (15mg) and dexamethasone (20mg) in frail patients with relapsed or refractory MM.
- Trial name
- LENDER (NCT03809780)
- Testing
- Lenalidomide, Dexamethasone
- Where
- South Korea
- Volunteers
- 70 people
- Sponsor
- Kosin University Gospel Hospital
Lymphoma, Non-Hodgkin, Lymphoma, Follicular
Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell Lymphomas
This research study will only include two types of non-Hodgkin Lymphoma (NHL), follicular lymphoma or marginal zone lymphoma and participants will be age 70 or older.
- Conditions
- Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Low-Grade
- Trial name
- NCT01263418
- Testing
- Ofatumumab
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Multiple Myeloma
Ixazomib -Daratumumab Without Dexamethasone (IDara) in Elderly Relapse Refractory Multiple Myeloma
Multiple myeloma is an incurable hematological malignancy that affects older patients. Currently, despite recent progress, the disease relapses more or less quickly after initial treatment and requires the resumption of treatment…
- Trial name
- IDARA (NCT03757221)
- Testing
- Ixazomib and Daratumumab
- Where
- France
- Volunteers
- 55 people
- Sponsor
- University Hospital, Caen